Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sinopharm Kunming Blood Products is a prominent biopharmaceutical company based in Kunming, China, specializing in the production of plasma-derived medicines. As a subsidiary of Beijing Tiantan Biological Products under the China National Biotec Group (CNBG), it plays a critical role in Sinopharm's blood products division. The company operates a state-of-the-art manufacturing base in Yunnan province, which is one of the largest plasma fractionation facilities in Asia. Its core product portfolio includes human albumin, intravenous immunoglobulin (IVIG), and essential coagulation factors like Factor VIII and Prothrombin Complex. These products are vital for treating conditions such as immunodeficiencies, hemophilia, and various critical care scenarios. The company is integrated into Sinopharm's extensive supply chain, ensuring high standards of safety and efficacy through advanced viral inactivation and purification technologies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 国药集团昆明血液制品.